Management of patients with cirrhosis awaiting liver transplantation.

GI Unit, Institut Clinic de Malalties Digestives i Metaboliques, Hospital Clinic,and University of Barcelona, Institut d’Investigacions Biomédiques August Pi-Sunyer (IDIBAPS), Ciber de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.
Gut (Impact Factor: 10.73). 03/2011; 60(3):412-21. DOI: 10.1136/gut.2009.179937
Source: PubMed

ABSTRACT The demand for OLT continues to be on the rise with patients spending a long time on the waiting list; this not only increases the risk of developing further decompensation but also mortality. The complications discussed above may not only lead to removal from the waiting list in some cases but also a poorer outcome following transplantation. Therefore the appropriate prevention, recognition and treatment of the above-mentioned complications of cirrhosis will have a positive impact on the outcome before and after liver transplantation.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cirrhosis results from progressive fibrosis and is the final outcome of all chronic liver disease. It is among the ten leading causes of death in United States. Cirrhosis can result in portal hypertension and/or hepatic dysfunction. Both of these either alone or in combination can lead to many complications, including ascites, varices, hepatic encephalopathy, hepatocellular carcinoma, hepatopulmonary syndrome, and coagulation disorders. Cirrhosis and its complications not only impair quality of life but also decrease survival. Managing patients with cirrhosis can be a challenge and requires an organized and systematic approach. Increasing physicians' knowledge about prevention and treatment of these potential complications is important to improve patient outcomes. A literature search of the published data was performed to provide a comprehensive review regarding the management of cirrhosis and its complications.
    World Journal of Gastroenterology 05/2014; 20(18):5442-5460. · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute kidney injury (AKI) is frequent in patients with cirrhosis. AKI and hyponatremia are major determinants of the poor prognosis in advanced cirrhosis. The hepatorenal syndrome (HRS) denotes a functional and potential reversible impairment of renal function. Type 1 HRS, a special type of AKI, is a rapidly progressive acute kidney injury whereas the renal function in type 2 HRS decreases more slowly. HRS is precipitated by factors such as sepsis that aggravate the effective hypovolaemia in decompensated cirrhosis, by lowering arterial pressure and cardiac output and enhanced sympathetic nervous activity. Therefore, attempts to prevent and treat HRS should seek to improve liver function and to ameliorate arterial hypotension, central hypovolaemia, and cardiac output and to reduce renal vasoconstriction. Ample treatment of HRS is important to prevent further progression and death but since medical treatment only modestly improves long-term survival, these patients should always be considered for liver transplantation. Hyponatremia, defined as serum sodium < 130 mmol/l, is common in patients with decompensated cirrhosis. From a pathophysiological point of view, hyponatremia is related to an impairment of renal solute-free water excretion most likely due to an increased vasopressin secretion. Patients with cirrhosis mainly develop hypervolaemic hyponatremia. Current evidence does not support routine use of vaptans in the management of hyponatremia in cirrhosis.This article is protected by copyright. All rights reserved.
    Liver international: official journal of the International Association for the Study of the Liver 03/2014; · 3.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Autotaxin (ATX) and its product lysophosphatidic acid (LPA) are considered to be involved in the development of liver fibrosis and elevated levels of serum ATX have been found in patients with hepatitis C virus associated liver fibrosis. However, the clinical role of systemic ATX in the stages of liver cirrhosis was unknown. Here we investigated the relation of ATX serum levels and severity of cirrhosis as well as prognosis of cirrhotic patients. Methods: Patients with liver cirrhosis were prospectively enrolled and followed until death, liver transplantation or last contact. Blood samples drawn at the day of inclusion in the study were assessed for ATX content by an enzyme-linked immunosorbent assay. ATX levels were correlated with the stage as well as complications of cirrhosis. The prognostic value of ATX was investigated by uni-and multivariate Cox regression analyses. LPA concentration was determined by liquid chromatography-tandem mass spectrometry.
    PLoS ONE 07/2014; · 3.73 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014